Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00238732 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

A Phase 3 study of Vaginal Atrophy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
650
Enrollment target
20
Study locations

NCT00238732 is a Phase 3 study of Vaginal Atrophy that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 650 participants, above the 284-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00238732, a Phase 3 study of Vaginal Atrophy, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
650 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.

Conditions Studied

Vaginal Atrophy

Interventions

  • DRUG Bazedoxifene/Conjugated Estrogen

Study Locations (20)

Florida

  • - Aventura
  • - Gainesville
  • - Miami
  • - Palm Harbor
  • - Palm Springs
  • - Pinnellas Park
  • - Stuart
  • - Tampa
  • - West Palm Beach

California

  • - Oakland
  • - San Diego
  • - Upland

Connecticut

  • - Avon
  • - Groton
  • - Waterbury

Alabama

  • - Birmingham
  • - Montgomery

Arizona

  • - Scottsdale
  • - Tucson

Colorado

  • - Denver

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2005-10
Est. Completion 2007-03
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00238732

The ClinicalTrials.gov registry entry for NCT00238732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 284-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (129% higher). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Bazedoxifene/Conjugated Estrogen is the first listed.

NCT00238732 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00238732 about?

NCT00238732 is a clinical study titled "Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause". The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.

What is the current status of trial NCT00238732?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2005-10. Estimated completion is 2007-03.

What conditions does trial NCT00238732 study?

This clinical trial studies the following conditions: Vaginal Atrophy.

What interventions are being tested in trial NCT00238732?

The interventions under investigation include: Bazedoxifene/Conjugated Estrogen (DRUG).

Who is sponsoring clinical trial NCT00238732?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00238732 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Vaginal Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Vaginal Atrophy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.